Life Sciences Archive » November, 2008

Life Sciences - November, 2008

145 articles

• Complaints On Wyeth Outsourcing Led To Firing: Suit
• NationsHealth Workers Launch Unpaid Wage Action
• Lilly Shoots Off 2 More Cymbalta Suits
• Barr, Mylan Face Patent Suit Over Amrix ANDAs
• Melamine Traces Found In US Baby Formula
• Avandia Bigger Heart Risk Than Competitor: Study
• StarCaps Diet Pill Recalled For Unauthorized Diuretic
• Vaginal Deformity Claims To Proceed Against AMS
• Aredia Judge Tosses More Failure-To-Warn Claims
• J&J E-mails Link Research Center, Risperdal
• FDA Tells Cedax Maker To Fix Deceptive Marketing
• Minn. Supreme Court To Weigh In On Prempro MDL
• Roche, Apotex Drop One Patent In Spat Over Boniva
• Magistrate Rules On Motions In Crestor Patent MDL
• EU Report To Target Drug Patents, Lawsuits
• Bayer Pays $97.5M To Settle Kickback Allegations
• EU Raids Drug Cos. In Latest Antitrust Sting
• AstraZeneca Settles Pulmicort War With Teva
• Abbott, WARF Clash With Teva Over Zemplar
• Texas Eastern District: IP Equipoise?
• Lane Powell Ordered Off CellCyte Investor Suit
• GSK Parent Off The Hook In Paxil Birth Defect Suit
• Barr Settles With CVS, Walgreen But Not Meijer
• Officials Warn Of Deaths Linked To Bayer Drug
• Obama Could Raise Cap On H-1B Skilled Workers
• Medtronic Loses Jury Trial Bid In Defibrillator Suit
• PharmaNet Stock Plunge Prompts Class Action
• FDA Warns Of Epilepsy Drug Danger For Asians
• Quigley Urges Court To Overrule Insurance Protests
• Pfizer Wins Choice-Of-Law Appeal In Lipitor Actions
• Fed. Circ. Reverses Ruling In IV Patent Dispute
• McKesson Agrees To Settle AWP Case For $350M
• Calif. Supreme Court To Consider 'Pass-On' Defense
• GSK Ordered To Produce Paxil Ad Campaign Details
• Bracing For The Surge In Reimbursement Disputes
• Avastin-Chemo Combo Could Boost Clot Risk: Study
• Under Obama, IP Reforms May Still Come Slow
• Abbott Settles TriCor Class Action For $184M
• Eli Lilly, Princeton Fire Off Another Alimta Suit
• Roche Vows To Appeal $12.9M Accutane Verdict
• Sanofi Victorious In Arava Antitrust Class Action
• Court Reverses Obviousness Ruling In Andersen Case
• AstraZeneca Scores TRO Against Teva
• SEC Sues Traders Over Alleged Short-Sale Scheme
• Arthrex Hit With Injunction In Suture Anchor Suit
• Anticipating Obama's Consumer Protection Push
• General Growth Hires Sidley Austin Bankruptcy Attys.
• EU Calls For Suspension Of J&J's Ionsys
• Lilly Targets Actavis In Latest Cymbalta Patent Suit
• 1st Circ. Upholds NH Law On Prescription Data
• 'Straw Dogs' Unlikely To Doom Obama AG Nominee
• Novartis Spars With Sales Reps Over FLSA Exemptions
• Marriott Timeshare Salesman Sues For Overtime Pay
• Boehringer Sues To Block Norbrook's Generic Metacam
• Wyeth, Cordis Add Abbott To Medtronic Stent Spat
• Pa. Names Former GE Plant Hazardous Waste Site
• AstraZeneca, Teva Patent Spat Flares Up
• FDA Opens 3 Offices In China
• Sanofi To Get $60M In Allegra Deal With Barr, Teva
• Sun Pharma Fires Back At Biovail In Cardizem Suit
• Nev. Sues Wyeth, Pfizer Over Hormone Drugs
• Wyeth Asks For Delay In Patent Fight With Apotex
• DOJ Subpoenas Medtronic Over Bone Graft Product
• Schering Sues Sun, Caraco Over New Clarinex Patent
• Eli Lilly Circles Wagons Around Cymbalta Patent
• Alpharma Sues Purdue Over Painkiller Mktg. Rights
• 5th Circ. Rebuffs Insurers In Vioxx Settlement
• Jury Tags J&J Units To Pay $16M For Pain Patch Death
• Plavix: A Significant Decision For Patent Holders
• Pfizer Seeks To Limit Discovery In Quigley Ch. 11
• Pozen Sues Par Pharmaceutical Over Migraine ANDA
• Teva, Zydus Drop Some Claims In Coreg Patent Suit
• DOJ Takes Aim At Actavis' Drug-Making Practices
• Teva Contests 2 Of Gilead's Truvada Patents
• The 'Substantial Question Of Patentability' Defense
• Lawmakers Probe FDA Over Medical Device Review
• GSK Wins Bid To Boot Paxil Suicide Suit
• FDA Seeks Panel Expert Review Of Antibiotic
• Univ. Of Kansas Sues NIH Over Cancer Drug Patents
• Leaps and Bounds: Notable Firm News
• SEC Charges Ex-McKesson Exec With Insider Trading
• 4 Novartis Claims Dropped In Retisert Sales Spat
• Synthes Brandishes Patent Against Implant Maker
• Hotbed Of FLSA Claims To Continue In Low Economy
• EU Raids French Biomedical Analysis Firms
• US Attorneys' Offices' Resources Mismanaged: Audit
• Patent Litigation Evolves Slowly In Shaky Economy
• McKesson Manager Disgorges Insider Trading Spoils
• Orion Strikes At Sun Over Comtan ANDA
• Roche, Mutual Drop Part Of Suit Over Boniva
• Tort Victims Challenge Privilege In Quigley Ch. 11
• Bone Drugs Pose No Clear Threat To Heart: FDA
• Beleaguered Mall Owner Weighs Bankruptcy
• In Perspective: Federal Agency Standards Preemption
• FDA Eyes Alpharma's Embeda Over Abuse Effects
• Woman Slaps Pfizer With Lawsuit Over PCBs
• CR Bard Falls Short In Bid To Nullify Class
• Drug Co. Sues USPTO Over Patent Term Adjustment
• Forest Labs To Settle Shareholders' Suit For $65M
• A Broader Scope For American Pipe Tolling Doctrine
• Accentia Seeks Ch. 11 Shelter, Blames Credit Crunch
• Katz Inks Licensing Deals With 10 More Cos.
• Mo. Right Venue For Teva Amoxicillin Suit: Judge
• Looking At The Future Of Preemption
• Hope At Last For Drug Manufacturers Sued In NJ?
• Sedgwick Acquires Ft. Lauderdale Law Firm
• Consolidated 3rd-Party Payer Seroquel Case Tossed
• Ethex Issues Another Recall Of Oversize Pills
• SRU's 31 Sensor Patents Invalid, Sensor Maker Claims
• Teva Hears No Again In Risperdal Spat
• Court Denies Lilly Depositions In Zyprexa MDL
• Baltimore Targets McKesson For AWP Markups
• Wyeth Can Be Liable For Generic Warnings: Court
• Teva's Bid To Crack Attorney-Client Privilege Fails
• Obama's FDA Commissioner Pick Could Be Outsider
• Wyeth, Pfizer Face More Claims In Premarin Suit
• Fed. Circ. Upholds Bar On Generic Prevacid For Teva
• Innovator's Guide To Navigating CMS
• Bayer Sues Norbrook Over Bid For Livestock Drug
• 471,000 Mislabeled Insulin Syringes Recalled
• Baby Formula Makers' Case Transfer Request Denied
• Wyeth Settles With 4th Drug Co. Over Generic Effexor
• Asbestos Victims Demand Voice In Quigley Case
• FDA Takes Contaminated Heparin From Ohio Drug Co.
• Willfulness Claims Stricken In 4 ADHD Drug Suits
• Impax Sued Again Over Ultram ANDA
• Canada High Court Upholds Plavix 'Selection' Patent
• FDA Enforcement May Soon Extend To Tobacco
• Former Goldman Analyst May Have Fled US
• Calif. Fertility Clinic Hit With FDA Warning
• US Airways Settles De-Icer Product Liability Suit
• Judge: Corepharma Did Not Infringe Carbatrol Patent
• DOJ, State AGs Investigate Vytorin Marketing
• FDA Warns Caraco Over Violations At Drug Plant
• 9th Circ. Denies Dismissal To HBOC Fraud Defendants
• Plaintiff Bid To Disband Baycol MDL Nixed
• Abbott Sues Biovail Over Generic TriCor
• Genetic Researchers Clash Over Diagnostic Patents
• Cephalon Sues Barr Again Over Generic Fentora ANDA
• Future Product Liability Law In Hands Of High Court
• Roche Wins Judgment In Accutane Suicide Case
• Sheppard Mullin Lands 13th Heller Partner For Year
• DOJ Eyes AtriCure Over Marketing Practices
• Wyeth V. Levine In Light Of Merck's Vioxx Litigation
• Omnicare Faces 2 Qui Tam Antitrust Fraud Suits